Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.51 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.49 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.49 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393217 | 1.00 | MAP2K1 (0.51) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL390658 | 0.93 | MAP2K1 (0.59) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL390659 | 0.93 | MAP2K1 (0.59) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL392312 | 0.92 | MAP2K1 (0.49) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL392311 | 0.92 | MAP2K1 (0.49) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL392246 | 0.89 | MAP2K1 (0.49) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL392247 | 0.89 | MAP2K1 (0.49) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL391369 | 0.87 | MAP2K1 (0.67) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL391368 | 0.87 | MAP2K1 (0.67) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL392154 | 0.87 | MAP2K1 (0.65) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3340989-B1 | MDM2 INHIBITORS AND COMBINATIONS THEREOF | NOVARTIS AG (CH) | 2023-08-16 | — | — | EP | claimed |
| US-9446043-B2 | Pharmaceutical combinations | NOVARTIS AG (CH) | 2016-09-20 | — | — | US | claimed |
| US-20150306101-A1 | Pharmaceutical Combinations | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2015-10-29 | — | — | US | claimed |
| EP-2750675-A1 | SYNERGISTIC COMBINATIONS OF PI3K- AND MEK-INHIBITORS | Novartis AG (CH) | 2014-07-09 | — | — | EP | claimed |
| US-20140179744-A1 | SYNERGISTIC COMBINATIONS OF PI3K- AND MEK-INHIBITORS | NOVARTIS PHARMA AG (CH) | 2014-06-26 | — | — | US | claimed |
| WO-2013066483-A1 | SYNERGISTIC COMBINATIONS OF PI3K- AND MEK-INHIBITORS | NOVARTIS AG (CH) | 2013-05-10 | — | — | WO | claimed |
| EP-2361905-B1 | Heterocyclic Inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2013-03-06 | — | — | EP | claimed |
| WO-2012145503-A1 | PHARMACEUTICAL COMBINATIONS | NOVARTIS AG (CH) | 2012-10-26 | — | — | WO | claimed |
| EP-1922307-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2011-12-28 | — | — | EP | claimed |
| EP-2361905-A1 | Heterocyclic Inhibitors of MEK and methods of use thereof | Array Biopharma Inc. (US) | 2011-08-31 | — | — | EP | claimed |
| US-7732616-B2 | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-06-08 | — | — | US | claimed |
| EP-1922307-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-05-21 | — | — | EP | claimed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | claimed |
| WO-2007044084-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-04-19 | — | — | WO | claimed |
| US-20230398115-A1 | MDM2 INHIBITORS AND COMBINATIONS THEREOF | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230398115-A1 | MDM2 INHIBITORS AND COMBINATIONS THEREOF | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| EP-4241850-A2 | MDM2 INHIBITORS AND COMBINATIONS THEREOF | Novartis AG (CH) | 2023-09-13 | — | — | EP | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2007044084-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | MAP2K1 73/4885MAP2K2 63/4885MAP2K5 86/4885 |
| US-20230398115-A1 | MDM2 INHIBITORS AND COMBINATIONS THEREOF | TP53, MDM2, BCL2 | MAP2K1 85/4885MAP2K2 61/4885MAP2K5 137/4885 |
| US-20150306101-A1 | Pharmaceutical Combinations | MAP2K1, PRKACA, MAP2K2 | MAP2K1 1/4885MAP2K2 3/4885MAP2K5 9/4885 |
| US-20140179744-A1 | SYNERGISTIC COMBINATIONS OF PI3K- AND MEK-INHIBITORS | PIK3CA, MAP2K2, MAPKAP1 | MAP2K1 4/4885MAP2K2 2/4885MAP2K5 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.